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Abstract
Gliomas are the most frequently occurring primary brain tumor in the central nervous system of adults. Glioblastoma
multiformes (GBMs, WHO grade 4) have a dismal prognosis despite the use of the alkylating agent, temozolomide (TMZ),
and even low grade gliomas (LGGs, WHO grade 2) eventually transform to malignant secondary GBMs. Although GBM
patients benefit from promoter hypermethylation of the O
6-methylguanine-DNA methyltransferase (MGMT) that is the main
determinant of resistance to TMZ, recent studies suggested that MGMT promoter methylation is of prognostic as well as
predictive significance for the efficacy of TMZ. Glioma-CpG island methylator phenotype (G-CIMP) in the global genome was
shown to be a significant predictor of improved survival in patients with GBM. Collectively, we hypothesized that MGMT
promoter methylation might reflect global DNA methylation. Additionally in LGGs, the significance of MGMT promoter
methylation is still undetermined. In the current study, we aimed to determine the correlation between clinical, genetic, and
epigenetic profiles including LINE-1 and different cancer-related genes and the clinical outcome in newly diagnosed 57 LGG
and 54 GBM patients. Here, we demonstrated that (1) IDH1/2 mutation is closely correlated with MGMT promoter
methylation and 1p/19q codeletion in LGGs, (2) LINE-1 methylation levels in primary and secondary GBMs are lower than
those in LGGs and normal brain tissues, (3) LINE-1 methylation is proportional to MGMT promoter methylation in gliomas,
and (4) higher LINE-1 methylation is a favorable prognostic factor in primary GBMs, even compared to MGMT promoter
methylation. As a global DNA methylation marker, LINE-1 may be a promising marker in gliomas.
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Introduction
Glioblastoma multiforme (GBM, WHO grade 4) is one of the
most frequently occurring brain tumors in the primary central
nervous system of adults and is highly malignant. The median
survival time is 14 months from diagnosis, despite the use of
aggressive treatment, surgery, postoperative radiotherapy, and
adjuvant temozolomide (TMZ)-based chemotherapy [1,2,3]. The
efficacy of TMZ for treating GBM is often very limited because of
inherent or acquired resistance. The main determinant of
resistance to alkylating agents is O
6-methylguanine-DNA methyl-
transferase (MGMT); this enzyme directly and specifically
eliminates the cytotoxic alkyl adducts formed at the O
6 position
of guanine and less frequently at the O
4 position of thymine
[4,5,6]. A subanalysis in an international randomized trial by the
European Organization for Research and Treatment of Cancer/
National Cancer Institute of Canada (EORTC/NCIC) compared
the results of radiotherapy alone with those of concomitant
radiotherapy and TMZ and showed that epigenetic silencing of
the MGMT gene by promoter methylation increased the survival
time of patients with primary GBM [3,7]. MGMT has been used
as a therapeutic target because downregulation of MGMT may
enhance the chemosensitivity of malignant gliomas to TMZ. Thus,
MGMT has been regarded as a predictive factor in the treatment
of GBM patients. Although the predictive value of MGMT
methylation has largely been confirmed in numerous prospective
and retrospective clinical investigations, it is unclear if this is
directly due to reduced MGMT expression. Indeed, evidence has
shown that MGMT promoter hypermethylation is better correlat-
ed with survival benefit than evaluations of its mRNA and protein
levels [8,9]. In addition, Van den Vent et al reported that a
methylated MGMT promoter was of prognostic significance
among patients with anaplastic gliomas treated with radiation
alone [10]. These results suggest that a methylated MGMT
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23332promoter is prognostic as well as predictive for the outcome of
adjuvant therapy in high-grade gliomas [11].
Cancer-specific DNA methylation changes are hallmarks of
human cancers, with global DNA hypomethylation often seen
concomitantly with hypermethylation of CpG islands [12]. A CpG
island methylator phenotype (CIMP) is regarded as cancer-specific
CpG island hypermethylation of a subset of genes in some tumors
[13]. Colorectal CIMP is associated with microsatellite instability
and transcriptional silencing [14]. Recently, The Cancer Genome
Atlas (TCGA) project and other groups have attempted to profile
GBM genes comprehensively based on genomic and epigenomic
aberrations and transcriptomal features [1,15,16]. In GBM,
glioma-CIMP status (G-CIMP) was shown to be a significant
predictor of improved patient survival [16]. Collectively, these
different sets of observations suggest that the level of MGMT
promoter methylation, serving as a prognostic factor, may reflect
an aspect of the global DNA methylation status in GBM.
Recently, long interspersed nuclear element-1 (LINE-1) has
attracted attention. LINE-1 is a non-long terminal-repeat class of
retroposons that is the most successfully integrated mobile element
in the human genome and accounts for approximately 18% of the
human genome [17]. The level of LINE–1 methylation is regarded
as a surrogate of global DNA methylation. In various cancers such
as colon and ovarian cancer, it is thought that hypomethylation of
LINE-1 is correlated with poor prognosis [17,18,19]. However, in
glioma patients, the level of LINE-1 methylation has not been fully
estimated. Recently, many studies have suggested that low-grade
gliomas (LGGs, WHO grade 2) including astrocytoma (As),
oligodendroglioma (OG) and oligoastrocytoma (OA) display a
highly methylated profile, in particular LGGs with mutated IDH1
[20,21].
In the current study, we aimed to determine the correlation
between clinical, genetic, and epigenetic profiles of LINE-1 and of
different cancer-related genes and the clinical outcome in newly
diagnosed LGG and GBM patients. Here, we demonstrated that
(1) LINE-1 methylation levels in primary and secondary GBMs are
lower than those in LGGs and normal brain tissues, (2) LINE-1
methylation is directly proportional to MGMT promoter methyl-
ation in gliomas, and (3) higher LINE-1 methylation is a favorable
prognostic factor in primary GBMs. As a global DNA methylation
marker, LINE-1 may be a promising marker reflecting the MGMT
promoter methylation and the G-CIMP status.
Materials and Methods
Ethics Statement
The study was approved by the institutional review board at
each participating hospital and complied with all provisions of the
Declaration of Helsinki.
Patients and Tumor Samples
We collected 111 freshly frozen tissues from patients with LGGs
(WHO grade 2), or GBMs treated at Nagoya University Hospital,
Oita University Hospital, Hamamatsu University Hospital, and
Shizuoka Cancer Center. Their clinical characteristics are
summarized in Table 1. Of 57 LGG patients, 30 patients with
residual tumor evaluated by T2-wighted magnetic resonance
imaging (MRI) received adjuvant nitrosourea-based or TMZ-
based chemotherapy concomitant with radiotherapy (large focal
40 Gy) immediately after initial surgery. All primary GBM patients
received TMZ–based chemotherapy and radiotherapy (60 Gy)
following initial surgery. Secondary GBM was defined as a prior
histological diagnosis of LGG.
Tumor Samples
DNA was prepared using the QIAmp DNA Mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
The amount of DNA obtained from the tumor was sufficient for
the subsequent genomic and epigenomic analyses.
Multiplex Ligation-Dependent Probe Amplification
Multiplex ligation-dependent probe amplification (MLPA) was
used to determine allelic losses and gains in the tumor samples.
The analysis was performed using the SALSA MLPA KIT P088-
B1 and P105-C1 in accordance with the manufacturer’s protocol
(MRC Holland, Amsterdam, Netherland) [22]. Information
regarding the probe sequences and ligation sites can be found at
www.mlpa.com. Amplification products were separated on an
ABIH 31306I Genetic Analyzer (Applied Biosystems, Foster City,
CA) and quantified with Genemapper 4.0 software (Applied
Biosystems). Data analysis was performed with an original Excel-
based program based on MRC-Holland’s procedures. Normali-
zation for sample data was first performed on control probes, and
each tumor sample was then normalized using the data on 2
control samples, using peripheral blood DNA. Single regression
for control and tumor data slope correction was performed.
Abnormal/normal ratio limits were set at 0.65 and 1.3. Statistical
analysis was performed using the same Coffalyser software.
Pyrosequencing
Tumor DNA was modified with bisulfate using the EpiTect
bisulfite kit (Qiagen). Pyrosequencing technology was used to
determine the methylation status of the CpG island region of the
MGMT promoter and LINE-1, as described previously [18,23].
We used the touchdown PCR method for the MGMT promoter
and the conventional PCR method for LINE-1. The primer
sequences used were the MGMT forward primer (59-
TTGGTAAATTAAGGTATAGAGTTTT-39), the MGMT bioti-
nylated reverse primer (59-AAACAATCTACGCATCCT-39), the
LINE-1 forward primer, (59-TTTTGAGTTAGGTGTGGGA-
TATA-39), and the biotinylated reverse primer (59-AAAAT-
CAAAAAATTCCCTTTC-39). PCR for the MGMT promoter
included a denaturation step at 95uC for 30 s, followed by
annealing at various temperatures for 45 s, and extension at 72uC
for 45 s. PCR for LINE-1 included a denaturation step at 95uC for
Table 1. Clinical characteristics.
Baseline characteristics of all gliomas
(n=111)
Histological
subgroups No. Age, years Sex
median range male (%) female (%)
Grade 2 gliomas 57 42.0 21–72 36 (63%) 21 (37%)
As 17 40.0 23–72 13 (76%) 4 (24%)
OG 29 44.0 21–61 17 (59%) 12 (41%)
OA 11 48.0 26–68 6 (55%) 5 (45%)
GBMs 54 59.0 12–84 33 (61%) 21 (39%)
pGBMs 51 59.2 12–84 31 (61%) 20 (39%)
sGBMs 3 42.0 21–50 2 (67%) 1 (33%)
As; Astrocytoma, OG; Oligodendroglioma, OA; Oligo-astrocytoma, pGBMs;
primary GBMs, sGBMs; secondary GBMs.
doi:10.1371/journal.pone.0023332.t001
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After PCR, the biotinylated PCR product was purified as
recommended by the manufacturer. In brief, the PCR product
was bound to streptavidin sepharose HP (Amersham Biosciences,
Uppsala, Sweden), and the sepharose beads containing the
immobilized PCR product were purified, washed, and denatured
using a 0.2 N NaOH solution, and then washed again. Next,
0.3 mM pyrosequencing primer was annealed to the purified
single-stranded PCR product, and pyrosequencing was performed
using the PSQ HS 96 Pyrosequencing System (Pyrosequencing,
Westborough, MA). The pyrosequencing primer for the MGMT
promoter was 59–GGAAGTTGGGAAGG-39 and for LINE-1
was 59–AGTTAGGTGTGGGATATAGT-39. Methylation was
quantified using the provided software.
TP53 and IDH1/IDH2 Sequencing
Direct sequencing of TP53 exons 5 to 8 and IDH1/2 was
performed as previously described [24,25]. The primer sequences
are listed in Table 2. For IDH sequencing, 2 fragments were
amplified: (1) a 129-bp fragment spanning the sequence encoding
the catalytic domain of IDH1, including codon 132 and (2) a 150-
bp fragment spanning the sequence encoding the catalytic
domain of IDH2, including codon 172. For sequencing TP53,
we applied touchdown PCR using the standard buffer conditions;
the reaction mixture included 5 ng of DNA and AmpliTaq Gold
DNA Polymerase (Applied Biosystems). The reaction was run for
16 cycles with denaturation at 95uC for 30 s, annealing at 65–
57uC (decreasing by 0.5uC per cycle) for 30 s, and extension at
72uC for 60 s, in a total volume of 12.5 ml. Then, an additional
30 cycles were performed with denaturation at 95uC for 30 s,
annealing at 55uC for 30 s, and extension at 72uC for 60 s,
ending at 72uC for 7 min to complete extension. Direct
sequencing was performed using the BigDye Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems). The reactions were
carried out using an ABI 3100 Genetic Analyzer (Applied
Biosystems). For IDH1/2 mutations, we applied conventional
PCR at 35 cycles with denaturation at 95uC for 30 s, annealing at
56uC for 40 s, and extension at 72uC for 50 s, ending at 72uCf o r
7 min to complete extension.
Statistical Analysis
Statistical analysis was performed using the statistical software
SPSS for Windows, version 19.0 (SPSS Inc, Chicago,I ll). The
Mann-Whitney U test, the Student’s t-test, the x
2 test, and the
Fisher exact test were used to test for the association of clinical
variables and molecular markers. Correlation of methylation level
between MGMT promoter and LINE-1 was analyzed by using
Spearman rank correlation coefficient, and analyzed by using
Pearson product - moment correlation coefficient in LGGs.
Survival was estimated by using the Kaplan-Meier method, and
survival curves were compared by using the log-rank test. Overall
survival (OS) was calculated from the day of initial surgery until
death or the end of follow-up, and progression-free survival (PFS)
was until tumor progression or re-treatment. Among LGGs,
univariate and multivariate analyses were performed to test the
potential influence of baseline characteristics on OS and PFS. The
effect of each single factor on OS and PFS was investigated using
the Cox proportional hazards model, adjusting for the major
clinical prognostic factors, including age at diagnosis (,40 vs.
$40), Sex (male vs. female), Eastern Cooperative Oncology Group
(ECOG) performance status score (ECOG PS; #1 vs. .1), extent
of resection (macroscopic [gross] total resection [GTR] or subtotal
resection [STR] vs. partial resection or biopsy), MGMT promoter
methylation status, chromosome 1p loss of heterozygosity (LOH),
19q LOH, PTEN loss, CDKN2A loss, TP53 loss and mutation,
ERBB2 amplification, EGFR amplification, IDH1 and IDH2
mutation, and adjuvant therapy immediately following the surgery
(with radiotherapy or chemotherapy vs. none). The factors in the
multivariate proportional hazard model (p,0.05) were considered
independent factors correlated with prolongation of OS and PFS.
Results
Frequency of Genetic and Epigenetic Alterations in LGGs,
and Primary and Secondary GBMs
We used direct sequencing for TP53 and IDH1/2 and employed
MLPA for the analysis of 1p/19q loss, PTEN and CDKN2A loss,
and amplification of ERBB2 and EGFR. Moreover, we used
pyrosequencing technology for quantitative estimation of the
methylation status of the MGMT promoter and LINE-1. Based on
comparisons using standard methylation-specific PCR and
immunohistochemical studies using the anti-MGMT antibody,
we determined 14% as the threshold distinguishing unmethylation
from methylation of the MGMT promoter in a given tumor, as
reported previously [26]. The data are summarized in Table 3 and
Figure 1. In LGGs, IDH1/2 mutation and methylation of the
MGMT promoter were frequently observed (,80%). Of the 46
tumors with IDH1 mutations, 44 exhibited R132H, one R132G,
and one R132S. The 1p/19q codeletion was detected more often
in OG (72%) than in As (6%) and OA (18%). In contrast, TP53
mutation was more frequently observed in As (41%) and OA
(45%) than in OG (10%). We did not detect amplification of EGFR
and ERBB2 in LGGs. In comparison with primary GBM,
secondary GBM had more IDH1/2 and TP53 mutations and
CDKN2A loss, a higher frequency of methylated MGMT promoter,
and less EGFR amplification, although the number of secondary
GBM (n=3) was limited (Table 3, Figure 1B).
Recently, emerging evidence revealed correlations between the
methylation status of the MGMT promoter, IDH1 mutations, and
1p/19q codeletions [27,28,29,30]. Using the x
2 test in LGGs,
IDH1/2 mutation was correlated significantly with a methylated
MGMT promoter (p=0.038) and 1p/19q codeletion (p=0.024).
Further, the presence of a methylated MGMT promoter was
correlated significantly with 1p/19q codeletion (p=0.026). Addi-
Table 2. List of Primer Sequences for Direct DNA Sequencing.
Gene name Exon Sequence
TP53 Exon 5 F 59-TTATCTGTTCACTTGTGCCC-39
R5 9-ACCCTGGGCAACCAGCCCTG-39
Exon 6 F 59-ACGACAGGGCTGGTTGCCCA-39
R5 9-CTCCCAGAGACCCCAGTTGC-39
Exon 7 F 59-GGCCTCATCTTGGGCCTGTG-39
R5 9-CAGTGTGCAGGGTGGCAAGT-39
Exon 8 F 59-CTGCCTCTTGCTTCTCTTTT-39
R5 9-TCTCCTCCACCGCTTCTTGT-39
IDH1 F5 9-CGGTCTTCAGAGAAGCCATT-39
R5 9-GCAAAATCACATTATTGCCAAC-39
IDH2 F5 9-AGCCCATCATCTGCAAAAAC-39
R5 9-CTAGGCGAGGAGCTCCAGT-39
F indicates forward primer, R,reverse primer.
doi:10.1371/journal.pone.0023332.t002
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Grade 2 gliomas GBMs Total
As OG OA pGBMs* sGBMs
n=17 n=29 n=11 n=51 n=3 n=111
IDH1/2 mutation 14 (82%) 24 (83%) 9 (82%) 3 (6%) 2 (67%) 52 (47%)
TP53 mutation 7 (41%) 3 (10%) 5 (45%) 19 (37%) 3 (100%) 37 (33%)
1p LOH 1 (6%) 21 (72%) 2 (18%) 4 (8%) 1 (33%) 29 (26%)
19q LOH 7 (41%) 22 (76%) 4 (36%) 5 (10%) 1 (33%) 39 (35%)
1p/19q codeletion 1 (6%) 21 (72%) 2 (18%) 4 (8%) 0 28 (25%)
PTEN loss 2 (12%) 0 0 4 (8%) 0 6 (5%)
CDKN2A loss 1 (6%) 1 (3%) 1 (9%) 20 (39%) 3 (100%) 26 (23%)
ERBB2 amplification 0001 ( 2 % ) 01 ( 1 % )
EGFR amplification 0002 5 ( 49%) 0 25 (23%)
Methylated MGMT 12 (71%) 24 (83%) 8 (73%) 16 (31%) 2 (67%) 62 (56%)
LINE-1 methylation** 67.663.0 69.062.6 70.062.3 66.664.1 60.761.8 67.663.6
As; Astrocytoma, OG; Oligodendroglioma, OA; Oligo-astrocytoma, pGBMs; primary GBMs, sGBMs; secondary GBMs.
*Motomura K et al reported these alterations of primary GBMs previously [26].
**LINE-1 methylation indicates mean methylation level 6 S.D. (%).
doi:10.1371/journal.pone.0023332.t003
Figure 1. Correlations between the methylation status of the MGMT promoter, IDH1/2 mutations, and 1p/19q deletions, higher LINE-
1 methylation in low-grade gliomas (LGGs), EGFR amplification, MGMT promoter, IDH1/2 mutations, high LINE-1 methylation in
primary and secondary GBMs. Using the x
2 test in grade 2 gliomas, IDH1/2 mutation was correlated significantly with a methylated MGMT
promoter (p=0.038) and 1p/19q codeletion (p=0.024). Further, the presence of a methylated MGMT promoter was correlated significantly with 1p/
19q codeletion (p=0.026). Additionally, of the 24 cases with 1p/19q codeletion, 23 and 22 cases exhibited IDH1/2 mutations and methylated MGMT
promoters, respectively, but none showed TP53 mutations. Of the 44 cases with methylated MGMT promoters, 39 cases exhibited IDH1/2 mutations
(A). In primary and secondary GBMs, EGFR amplification, which is the most frequent, and methylated MGMT promoter, IDH1/2 mutation and high
LINE-1 methylation was shown (B).
doi:10.1371/journal.pone.0023332.g001
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multiforme (GBM), and between grade 2 astrocytomas and oligodendroglial tumors. A higher proportion of LGGs including astrocytoma,
oligodendroglioma, and oligoastrocytoma, exhibited a methylated MGMT promoter (A) and LINE-1 (B) compared to GBMs, although the level of LINE-
1 in GBMs varied (see also Table 3). Compared among histological subgroups, the level of LINE–1 methylation in astrocytomas was significantly lower
than that in oligodendroglial tumors (B), which was similar to the MGMT promoter methylation (A). Horizontal line in the graph indicated the mean
level.
doi:10.1371/journal.pone.0023332.g002
Figure 3. LINE-1 methylation is directly proportional to MGMT promoter methylation in gliomas. MGMT promoter methylation level was
directly proportional to LINE–1 methylation in a statistically significant manner (r=0.335, p,0.001) for all samples quantified, including LGGs, primary
and secondary GBMs, and normal brain tissue. Cut-off line of LINE-1 methylation, MGMT promoter methylation was indicated.
doi:10.1371/journal.pone.0023332.g003
Methylated LINE-1 as a Prognostic Factor in Glioma
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exhibited IDH1/2 mutations and methylated MGMT promoters,
respectively, but none showed TP53 mutations. Of the 44 cases
with methylated MGMT promoters, 39 cases exhibited IDH1/2
mutations. These results suggest that almost all patients having
tumors with 1p/19q codeletions exhibited methylated MGMT
promoters and that almost all tumors with methylated MGMT
promoters exhibited IDH1/2 mutations (Figure 1A).
LINE-1 Methylation Is Proportional to MGMT Promoter
Methylation in gliomas
The level of LINE–1 methylation is regarded as a surrogate of
global DNA methylation. Recently, many studies have suggested
that low-grade gliomas (LGGs, WHO grade 2) including
astrocytoma (As), oligodendroglioma (OG) and oligoastrocytoma
(OA) display a highly methylated profile [20,21]. We examined
the level of LINE-1 methylation in comparison with that of
MGMT promoter methylation in glioma patients. To date, studies
have revealed that the level of methylated MGMT promoters
among LGGs was higher than that among GBMs [20,30,31].
Similar to the previous reports, a higher proportion of LGGs
exhibited a methylated MGMT promoter and LINE-1 compared
to GBMs, although the level of LINE-1 in GBMs varied [MGMT,
mean 18.9% vs. 31.9% (p,0.001); LINE-1, 66.2% vs. 68.8%
(p,0.001); Table 3 and Figure 2AB]. Compared among
histological subgroups, the level of LINE–1 methylation in As
was significantly lower than that in oligodendroglial tumors,
including OG and OA, which was similar to the MGMT
promoter methylation (mean LINE-1 methylation level, 67.6%
vs. 69.3%; p=0.036, Figure 2B).
The results described above prompted us to analyze the
correlation between the quantitative methylation values of
LINE-1 and the MGMT promoter. We found that the MGMT
promoter methylation level was directly proportional to LINE–1
methylation in a statistically significant manner (r=0.335,
p,0.001) for all glioma samples and normal brain tissue
(Figure 3). However, while LINE-1 methylation is significantly
proportional to MGMT promoter in LGGs (r=0.336, p=0.011),
statistical significance was not found when primary GBMs only
were analyzed, probably due to non-parametric distribution of the
MGMT promoter methylation level (Figure S1AB).
Previously, it was reported that G-CIMP tumors are more
prevalent among LGGs, and are tightly associated with IDH1
mutation [16]. Thus, it may be interesting to know whether
LINE-1 methylation is correlated with IDH1 mutation in our
sample sets. Although we did not observe the significant
correlation between IDH1/2 mutation and higher LINE-1
methylation both among LGGs and GBMs (Figure S2), we
showed that LGGs exhibited higher LINE-1 methylation than
GBMs did, and oligodendroglial tumors showed higher LINE-1
methylation than astrocytomas (Table 3, Figure 2B), which was
consistent with the previous report demonstrating that LGGs, in
Figure 4. Clinical, genetic, and epigenetic parameters in correlation with progression-free survival (PFS) and overall survival (OS) in
low-grade glioma patients. The presence of 1p/19q codeletion and the extent of resection were independently correlated with prolonged PFS, as
shown with multivariate analysis (p=0.014 and p=0.016, respectively). The presence of 1p/19q codeletion, the extent of resection and the age were
correlated with prolonged OS (p=0.013, 0.042, 0.016, respectively).
doi:10.1371/journal.pone.0023332.g004
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positive group.
Clinical, Genetic, and Epigenetic Parameters in
Correlation with PFS and OS in Low-grade Glioma
Patients
We investigated the correlations of the genetic and epigenetic
alterations with OS and PFS among LGGs. Among all LGGs,
the median PFS was 45.7 months (95% confidence interval [CI]:
17.1–74.3 months), the median OS was 172.8 months (95%CI;
8.9–336.8 months). Patients with As, OG, and OA had a PFS of
45.1, 74.9, and 37.3 months, respectively. As shown in Figure 4,
the presence of 1p/19q codeletion, the extent of resection were
independently correlated with PFS, as shown with multivariate
analysis (p=0.014, 0.016), and the presence of 1p/19q
codeletion, the extent of resection and the age were correlated
with prolonged OS (p=0.013, 0.042, 0.016, respectively). Using
al o g - r a n kt e s t ,au n i v a r i a t ea n a lysis revealed that prolonged
PFS and OS was significantly correlated only with the presence
of 1p/19q codeletion (p=0.013, p=0.013, supplementary
Figure S3AB). Univariate analysis showed that a methylated
MGMT promoter was not significantly correlated with pro-
longed PFS (p=0.128); however, if patients undergoing partial
removal or biopsy at initial surgery were selected, it became
significantly correlated with PFS (p=0.017, supplementary
Figure S4). Of particular note, high LINE-1 methylation (68%
#) was significantly correlated with prolonged OS of patients
aged over 40 (p=0.039), whereas statistical significant associ-
ation was not obtained between high LINE-1 methylation and
PFS (Figure 5).
Figure 5. High LINE-1 methylation status in correlation with progression-free survival (PFS) and overall survival (OS) in low-grade
glioma patients. In the Kaplan-Meier survival curve of patients with LGGs, High LINE-1 methylation status was not correlated with PFS in LGGs,
using log-rank test (p=0.364); (A). However in correlation with OS, in LGGs aged over 40, High LINE-1 methylation prolonged OS (p=0.039), black line
indicated the Kaplan-Meier survival curve of all LGGs (high LINE-1 methylation and low), red line LGGs aged over 40 (B).
doi:10.1371/journal.pone.0023332.g005
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GBMs
Next, we examined whether LINE-1 could be a prognostic
factor in primary GBMs. To our surprise, in the Kaplan-Meier
survival curve of patients with primary GBM, univariate analysis
indicated a lower p value in the comparison of ,68% and $68%
of LINE-1 methylation than in the comparison of ,14% and
$14% of MGMT promoter methylation (p=0.010 and 0.015,
Figure 6AB). Furthermore, in multivariate analysis, the hazard
ratio was computed using a proportional hazard model by selected
factors. Prolonged overall survival time was significantly correlated
with a high LINE-1 methylation status but not with a methylated
MGMT promoter (p=0.031, Figure 6C).
Genetic and Epigenetic Changes From Low-grade Glioma
to Secondary GBM
We experienced 3 secondary GBM cases and obtained serial
tumor samples of 2 cases at the time of grade 2 glioma (As and
OA) and at the time of progression to GBM. The secondary GBM
tumors already had TP53 mutation and IDH1 mutation at the
time of the low-grade tumors but displayed a 2-fold increase in
methylation of the MGMT promoter and an 8% decrease in
methylation of LINE-1 during malignant transformation.
Discussion
Previously, we demonstrated clinical, genetic, and epigenetic
profiles in newly diagnosed primary GBMs [26]. In this study, we
extended those analyses to LGGs, in comparison with GBMs. We
also included secondary GBMs in order to provide a possible clue
into the profile changes that occur during malignant transforma-
tion. Of great interest, the principal and novel finding of the
current study is that a global DNA methylation surrogate, LINE-1
methylation, is positively proportional to the MGMT promoter
methylation in gliomas.
In this study, 57 LGG samples exhibited IDH1/2 mutations
most frequently (82%), followed by methylated MGMT promoters
(77%), 1p/19q codeletion (42%), and TP53 mutations (26%). Our
results were consistent with data reported previously
[20,32,33,34,35]. We demonstrated that higher methylation levels
of LINE-1 and the MGMT promoter and 1p/19q codeletion were
associated with oligodendroglial tumors. Additionally, the pres-
ence of 1p/19q codeletion was significantly correlated with higher
MGMT promoter methylation.
Of these alterations, 1p/19q codeletion was most strongly
correlated with prolonged OS and PFS in both univariate and
multivariate analysis of LGGs. In our study, IDH1/2 mutation was
not correlated with prolonged PFS and OS in LGG patients. The
Figure 6. LINE-1 methylation is a better prognostic indicator in primary GBMs. In the Kaplan-Meier survival curve of patients with primary
GBM, univariate analysis indicated a lower p value in the comparison of ,68% and $68% of LINE-1 methylation (A) than in the comparison of ,14%
and $14% of MGMT promoter methylation (B). In multivariate analysis, the hazard ratio was computed using a proportional hazard model by selected
factors. Prolonged overall survival time was significantly correlated with a high LINE-1 methylation status but not with a methylated MGMT promoter
(C).
doi:10.1371/journal.pone.0023332.g006
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IDH1/2 mutations are not a prognostic factor for LGGs [27,36],
but there was opposed evidence showing significant and
independent associations between IDH mutation and improved
survival in LGGs [21,32]. The prognostic significance of IDH1/2
mutation in LGGs remains controversial.
To date, MGMT promoter methylation has been regarded as a
prognostic as well as predictive for the outcome to adjuvant
chemotherapy [10]. In various cancers, such as colorectal cancer,
global DNA hypomethylation was correlated with poor prognosis
[17,18]. We hypothesized that MGMT promoter hypermethylation
reflects global DNA hypermethylation in gliomas. To demonstrate
our hypothesis, we quantified the level of LINE-1 methylation in
gliomas. Higher methylation levels of LINE-1 and the MGMT
promoter were observed in LGGs than in GBMs (LINE-1: mean
68.8% vs. 66.2%, p,0.001; MGMT promoters: 31.9% vs. 18.9%,
p,0.001). Additionally, we investigated the correlations between
LINE-1 and MGMT promoter methylation levels. Among gliomas,
in particular LGGs, LINE-1 methylation levels were significantly
proportional to MGMT promoter methylation. Notably, only low
LINE-1 methylation indicated poor prognosis in primary GBM
patients, as analyzed by both univariate and multivariate analyses.
Prolonged overall survival time was significantly correlated with
high LINE-1 methylation status but not with a methylated MGMT
promoter. Additionally, higher LINE-1 methylation was correlated
with prolonged OS in LGG patients aged over 40. This is consistent
with other cancers such as colorectal cancer and ovarian cancer, in
which hypomethylation of LINE-1 is correlated with shortened
survival [17,18,37].
LINE-1 methylation and MGMT promoter methylation were
also correlated with tumor grading; LGGs displayed a higher
methylation level of LINE-1 and the MGMT promoter than
GBMs (WHO grade 4). Thus, in order to determine whether DNA
methylation relies on malignant transformation, we investigated
changes in genetic and DNA methylation patterns from LGGs to
secondary GBMs in identical cases. However, secondary GBMs
paradoxically displayed an increase in MGMT promoter methyl-
ation and a decrease in LINE-1 methylation. The limited number
of samples studied warrant further investigations.
Previously, it was reported that G-CIMP tumors are tightly
associated with IDH1 mutation [16]. More recently, IDH mutations
and resultant 2-hydroxyglutarate (2HG) production in leukemia cells
were reported to induce global DNA hypermethylation through
impaired TET2 catalytic function [38]. In this study, LGGs with
IDH1/2 mutation tended to exhibit higher LINE-1 methylation
althoughtherewasnostatisticalsignificance.Our studydemonstrated
the correlation of LINE-1 methylation with good prognosis among
GBMs for the first time,however, the mechanismwas not interpreted
and the numberof samplesin ourstudy waslimited. The higherlevels
of LINE-1 methylation in low grade gliomas may be attributable to
the differential prevalence of IDH mutation in low versus high-grade
glioma, and the methylator phenotype associated with IDH mutation.
Thus, interpreting LINE-1 methylation values for prognosis may be
more difficult than interpreting IDH1/2 mutation. We need further
investigation to validate our findings.
In summary, we demonstrated that LINE-1 methylation levels
in primary and secondary GBMs are lower than those in LGGs
and normal brain tissues, that LINE-1 methylation is directly
proportional to MGMT promoter methylation in gliomas, and that
higher LINE-1 methylation is a favorable prognostic factor in
primary GBMs. LINE-1 is a global DNA methylation marker,
which may be a promising marker reflecting the MGMT promoter
or the G-CIMP status.
Supporting Information
Figure S1 Correlation between the methylation levels of
LINE-1 and MGMT promoter. Among LGGs, LINE-1 is
derectly proportional to MGMT promoter, p=0.011, r=0.336
(A). However among primary GBMs, the correlation between the
methylation levels of LINE-1 and MGMT promoter are statisti-
cally insignificant, p=0.187, r=0.188 (B).
(TIFF)
Figure S2 Differences of methylation levels of LINE-1
between mutated IDH1/2 and wild-type. Among LGGs,
IDH1/2 mutation exhibited higher methylation level of LINE-1,
although insignificant, than wild-type IDH1/2, mean; 69.062.5%,
67.663.4%, p=0.144 (A). Among primary and secondary GBMs,
mutated IDH1/2 did not exhibited the differences of methylation
level of LINE-1, compared with wild-type IDH1/2 although we
analyzed only 5 mutated IDH1/2, mean; 65.564.8%,
66.364.2%, p=0.449 (B).
(TIFF)
Figure S3 1p/19q codeletions in correlation with over-
all survival, progression-free survival in low-grade
glioma patients. Using a log-rank test, a univariate analysis
revealed that prolonged PFS (A) and OS (B) was significantly
correlated only with the presence of 1p/19q codeletion.
(TIFF)
Figure S4 MGMT promoter methylation in correlation
with progression-free survival (PFS) in low-grade glioma
patients. Methylated MGMT promoter was not significantly
correlated with prolonged PFS (A); however, if patients undergo-
ing partial removal or biopsy at initial surgery were selected, it
became significantly correlated with PFS (B).
(TIFF)
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